To investigate the molecular mechanisms driving PRMT1-mediated inhibition of tumor growth in PDAC, we first employed a mass spectrometry-based proteomics approach (PTMScanR)25,26 to identify substrates methylated by PRMT1. The gene discussed is PRMT1; the disease is neoplasm.